All relevant data are within the manuscript.

Introduction {#sec001}
============

Japanese encephalitis (JE) is a vector-borne disease caused by JE virus (JEV), a single-stranded RNA flavivirus that is transmitted through a zoonotic cycle between mosquitoes, pigs and water birds, with humans as dead-end hosts. JEV is the primary vaccine-preventable cause of encephalitis and the major cause of viral encephalitis in Asia \[[@pntd.0008454.ref001]\]. Clinical outcomes of symptomatic JEV infection may vary from a mild non-specific febrile illness to a severe form of neuroinvasive disease carrying a high mortality rate (20--30%). However, most human infections with JEV are asymptomatic, with only 1% of JEV-infected patients proceeding to develop symptomatic clinical disease \[[@pntd.0008454.ref001]\].

JEV is considered endemic throughout Indonesia, as suggested by early serological studies in animals and humans \[[@pntd.0008454.ref002]--[@pntd.0008454.ref009]\], as well as from hospital-based surveillance for acute encephalitis syndrome (AES) \[[@pntd.0008454.ref010],[@pntd.0008454.ref011]\]. Cases of JEV infection in international tourists who have traveled to Bali, Indonesia have also been reported \[[@pntd.0008454.ref012]--[@pntd.0008454.ref015]\]. The presence of the virus in Indonesia has been confirmed by virus isolation from local mosquitos and pigs \[[@pntd.0008454.ref016]--[@pntd.0008454.ref020]\]. However, isolates from confirmed human cases have yet to be reported.

Studies from Indonesia have reported that death occurred in 10−16% of laboratory-confirmed JE cases while 31−37% of the survivors had neurological sequelae at hospital discharge \[[@pntd.0008454.ref010],[@pntd.0008454.ref011]\]. Long-term assessment of Indonesian children with JE disease showed that half of the children were either dead or left with serious disability \[[@pntd.0008454.ref021]\]. While the AES cases are well described, there is a limited description of symptomatic JEV infections without encephalitis. A study from Thailand reported that 14% of adults with acute undifferentiated fevers but without neurologic deficits were serologically diagnosed as JEV-infection \[[@pntd.0008454.ref022]\]. It is likely that JEV is also an under-recognized cause of fever in Indonesia. Here, with robust serological testing we report cases of JEV infection in non-encephalitic acute febrile illness patients from Bali, Indonesia.

Materials and methods {#sec002}
=====================

Ethics statement {#sec003}
----------------

This study was approved by the Medical Research Ethics Committee of Faculty of Medicine, Udayana University, Bali (ethical approval no. 98/UN.14.2/Litbang/2015 and 1452/UN.14.2/Litbang/2015) and the Eijkman Institute Research Ethics Commission (ethical approval no. 66). Written informed consent for participating in the study was obtained from all patients or the parents/guardians.

Study site, patient recruitment, and sample collection {#sec004}
------------------------------------------------------

Archived patient samples from a cross-sectional prospective study of dengue and acute febrile illness conducted in Wangaya General Hospital (Rumah Sakit Umum Daerah Wangaya) were analyzed. Wangaya General Hospital is located in Denpasar municipality of Bali province. This facility includes emergency room and intensive care units as well as inpatient wards and outpatient polyclinics for a wide variety of diseases. The hospital has 200 beds, 170,000 annual visits, and serves a population of 880,000. Inpatient admissions come from both emergency room and outpatient polyclinics. The leading diagnosis of patients admitted to emergency room, inpatient, and outpatient care were unspecified fever, dengue hemorrhagic fever, and diabetes mellitus, respectively. The study was conducted from March to May 2015 and September 2015 to June 2016 to study dengue and other acute febrile illnesses with the details of enrollment criteria and dengue data already reported \[[@pntd.0008454.ref023]\]. In brief, patients presenting at the hospital with acute febrile illness (fever ≥38°C with onset ≤7 days) but without history of chronic illnesses, human immunodeficiency syndrome, cardiac disease, sepsis, local infections (e.g. cellulitis, abscess), or gastrointestinal and respiratory symptoms were enrolled after informed consent was signed. Patients were recruited by the clinical staff by routine clinical assessment, history taking, physical examination, and laboratory tests on enrollment and/or after initial investigation. Admission blood samples (S1) were collected during patient admission while discharge blood samples (S2) were collected whenever patients were discharged from the hospital. Demographic data of the patients and clinical information were collected at the initial admission and before discharge from the hospital.

DENV NS1 antigen detection and RT-PCR assays {#sec005}
--------------------------------------------

DENV infection was excluded by testing of the S1 sample for DENV NS1 antigen via the SD Bioline NS1 rapid test (Alere, Australia) and DENV RNA using the Simplexa Dengue Real-time RT-PCR Kit (Diasorin, Italy) or pan-flavivirus RT-PCR as described previously \[[@pntd.0008454.ref023],[@pntd.0008454.ref024]\]. Patients who were confirmed to have acute DENV infection were excluded from the study. Furthermore, pan-alphavirus RT-PCR was also performed to exclude chikungunya virus (CHIKV) infection as previously described \[[@pntd.0008454.ref024]\].

Anti-JEV and anti-DENV IgM ELISA {#sec006}
--------------------------------

The presence of anti-JEV IgM in S2 specimens was detected using JEV IgM antibody capture ELISA (JEV MAC-ELISA), developed by the U.S. Centers for Disease Control and Prevention (CDC) as previously described \[[@pntd.0008454.ref025]\]. Ratios of test serum sample optical density to negative control values (P/N) at 450 nm were calculated. Any sample with a P/N \>3 was considered positive while P/N values between 2--3 were considered equivocal. Positive and equivocal S2 specimens were further re-tested paired with corresponding S1 specimens to look for seroconversion. The presence of anti-DENV IgM was also tested in both S1 and S2 specimens by using the DENV MAC-ELISA, developed by the Armed Forces Research Institute of Medical Sciences (AFRIMS), Thailand. Serum samples with DENV MAC ELISA binding index results ≥40 U were considered positive \[[@pntd.0008454.ref026]\].

Plaque reduction neutralization test (PRNT) {#sec007}
-------------------------------------------

All specimens positive or equivocal by JEV MAC-ELISA were tested for the presence of neutralizing antibodies against JEV and DENV by PRNT. PRNT was performed with JEV strain Nakayama, DENV-1 strain PUO-359, DENV-2 strain PUO-218, DENV-3 strain PaH881/88, and DENV-4 strain 1228 as previously described \[[@pntd.0008454.ref027]\]. Briefly, 2-fold serial dilutions of serum were mixed with each challenge virus and incubated at 37°C for 1 hour. The antibody-virus mixture was then inoculated onto baby hamster kidney (BHK-21) cell monolayers for 5 days before plaques were counted. The neutralization titer was expressed as the inverse of the maximum serum dilution yielding a ≥90% reduction in plaque number (PRNT~90~).

The diagnosis was classified as either confirmed JEV, probable JEV, DENV, or flavivirus infection ([Table 1](#pntd.0008454.t001){ref-type="table"}, adapted from \[[@pntd.0008454.ref028]\]). Confirmed JEV infection was defined as those who were anti-JEV IgM-positive/equivocal in the S2 and/or S1 specimen with ≥4-fold increased anti-JEV PRNT~90~ titer in S2 from S1 and an anti-JEV PRNT~90~ titer ≥4-fold higher than any anti-DENV titer in S2. Probable JEV infection was defined as those who were anti-JEV IgM-positive/equivocal in the S2 and/or S1 specimen with increased anti-JEV PRNT~90~ titer in S2 from S1 specimen but did not have an anti-JEV PRNT~90~ titer ≥4-fold higher than any anti-DENV titer in S2 specimen and were anti-DENV IgM-negative in both S1 and S2 specimen. DENV infection was defined as patients who were anti-JEV IgM-positive/equivocal in the S2 and/or S1 specimen but with increased anti-DENV PRNT~90~ titer in S2 from S1 specimen alongside an anti-DENV PRNT~90~ titer ≥4-fold higher than anti-JEV titer in S2 specimen and anti-DENV IgM-positive in the S1 and/or S2 specimen. Finally, flavivirus infection was defined as those who were anti-JEV IgM-positive/equivocal in the S2 and/or S1 specimen but anti-JEV PRNT~90~ titer in S2 \<4-fold than any anti-DENV titer and with anti-DENV IgM-positive in the S1 and/or S2 specimen. The designation "probable JEV" was used because of the extensive cross-reactivity in secondary flavivirus infections; i.e. neutralizing antibody titers may be higher against a previous flavivirus infection rather than the most recent heterologous flavivirus infection as shown in other studies \[[@pntd.0008454.ref029]--[@pntd.0008454.ref033]\].

10.1371/journal.pntd.0008454.t001

###### Diagnostic interpretation of the serology testing results.

![](pntd.0008454.t001){#pntd.0008454.t001g}

  Diagnosis                                                              Criteria
  ---------------------------------------------------------------------- ----------------------------------------------------------
  Confirmed JEV                                                          Anti-JEV IgM-positive/equivocal in the S2 and/or S1, and
  Anti-JEV PRNT~90~ titer in S2 ≥4-fold higher from S1, and              
  Anti-JEV PRNT~90~ titer in S2 ≥4-fold higher than any DENV titer       
  Probable JEV                                                           Anti-JEV IgM-positive/equivocal in the S2 and/or S1, and
  Anti-JEV PRNT~90~ titer in S2 higher from S1, but                      
  Anti-JEV PRNT~90~ titer in S2 \<4-fold than any anti-DENV titer, and   
  Anti-DENV IgM-negative in the S1 and S2                                
  DENV                                                                   Anti-JEV IgM-positive/equivocal in the S2 and/or S1, but
  Anti-DENV PRNT~90~ titer in S2 higher from S1, and                     
  Anti-DENV PRNT~90~ titer in S2 ≥4-fold higher than JEV titer, and      
  Anti-DENV IgM-positive in the S1 and/or S2                             
  Flavivirus                                                             Anti-JEV IgM-positive/equivocal in the S2 and/or S1, but
  Anti-JEV PRNT~90~ titer in S2 \<4-fold than any anti-DENV titer, and   
  Anti-DENV IgM-positive in the S1 and/or S2                             

S1, admission serum sample; S2, discharge serum sample; PRNT, plaque reduction neutralization test.

Virus isolation {#sec008}
---------------

Virus isolation was attempted by inoculating patient S1 serum onto African green monkey kidney Vero cells as previously described \[[@pntd.0008454.ref024]\]. Cells were observed daily for cytopathic effects for up to 10 days.

Statistical analysis {#sec009}
--------------------

Statistical analysis was performed using OpenEpi v3.01 and GraphPad Prism v8. Quantitative data differences between groups were compared by unpaired Student t test for normally distributed data (based on D'Agostino-Pearson normality test) or by Mann-Whitney test for non-Gaussian distributed data. Categorical data were compared using Mantel-Haenszel chi-square test when all expected numbers are at least 1 or otherwise by using Fisher's exact test. *P*-values less than 0.05 were considered statistically significant.

Results {#sec010}
=======

During the study period, 3,677 patients with suspected dengue or acute febrile illness attended Wangaya Hospital and a total of 703 patients were enrolled in the study ([Fig 1](#pntd.0008454.g001){ref-type="fig"}). Of these, 321 patients had both admission (S1) and discharge (S2) paired serum specimens available and were included in this study analysis. One hundred forty-four patients showed no evidence of acute DENV infection (by detection of DENV NS1 Ag and/or RNA) nor CHIKV infection; these were tested for the presence of anti-JEV IgM. Of 144 patients, 26 (18.1%) were anti-JEV IgM-positive or equivocal in their S2 specimens ([Fig 1](#pntd.0008454.g001){ref-type="fig"}). All 26 were further tested for the presence of anti-DENV IgM and DENV/JEV neutralizing antibodies by PRNT in paired specimens, from which 5 (3.5%) and 8 (5.6%) met the criteria for confirmed JEV and probable JEV infection, respectively. The other 5 (3.5%) and 8 (5.6%) patients were classified as having DENV and flavivirus infection, respectively ([Table 2](#pntd.0008454.t002){ref-type="table"}). Cell culture and pan-flavivirus RT-PCR attempted from the S1 specimens did not produce any JEV positive results.

![Patient enrollment, specimens collected, and molecular and serological test performed.\
DENV NS1 antigen was detected by using SD Bioline NS1 rapid test while DENV RNA was detected using Simplexa Dengue Real-time RT-PCR Kit or pan-flavivirus RT-PCR. CHIKV RNA was detected using pan-alphavirus RT-PCR. Anti-JEV and anti-DENV IgM was detected by ELISA, while neutralizing antibodies against JEV and DENV were detected by plaque reduction neutralization test (PRNT).](pntd.0008454.g001){#pntd.0008454.g001}

10.1371/journal.pntd.0008454.t002

###### Serology testing results from non-encephalitic acute febrile illness patients with confirmed JEV, probable JEV, DENV, and flavivirus infection.

![](pntd.0008454.t002){#pntd.0008454.t002g}

  No.               Patient sample ID   Age (years)   Days after onset   IgM     PRNT~90~ titer                                     
  ----------------- ------------------- ------------- ------------------ ------- ---------------- --------- --------- ------ ------ ------
  JEV (confirmed)                                                                                                                   
  1                 WGY599 S1           20            3                  −       −                40        \<10      \<10   \<10   \<10
  WGY599 S2         6                   \+            \+                 1,280   20               80        20        20            
  2                 WGY623 S1           32            3                  −       −                \<10      \<10      \<10   \<10   \<10
  WGY623 S2         7                   \+            \+                 640     40               40        80        80            
  3                 WGY656 S1           23            2                  EQU     −                20        \<10      80     10     20
  WGY656 S2         3                   \+            −                  \>320   40               40        40        NA            
  4                 WGY726 S1           32            7                  \+      \+               80        10        40     80     10
  WGY726 S2         10                  \+            \+                 320     10               40        20        20            
  5                 WGY733 S1           15            4                  −       −                80        \<10      40     80     20
  WGY733 S2         7                   \+            \+                 320     10               40        80        20            
  JEV (probable)                                                                                                                    
  6                 WGY067 S1           22            4                  QNS     −                40        160       80     80     80
  WGY067 S2         7                   \+            −                  80      \>2,560          160       160       160           
  7                 WGY143 S1           4             7                  QNS     −                40        640       80     80     20
  WGY143 S2         12                  EQU           −                  160     \>2,560          160       160       80            
  8                 WGY317 S1           47            5                  \+      −                40        \<10      80     10     40
  WGY317 S2         8                   \+            −                  80      \<10             160       10        80            
  9                 WGY629 S1           19            5                  \+      −                160       20        160    80     160
  WGY629 S2         7                   \+            −                  320     320              1,280     160       320           
  10                WGY647 S1           27            5                  \+      −                80        160       80     40     80
  WGY647 S2         6                   \+            −                  160     1,280            20        160       80            
  11                WGY658 S1           30            3                  EQU     −                \<10      40        \<10   \<10   10
  WGY658 S2         5                   EQU           −                  80      80               \<10      \<10      \<10          
  12                WGY667 S1           6             5                  EQU     −                20        \<10      20     10     40
  WGY667 S2         7                   \+            −                  160     20               160       160       160           
  13                WGY713 S1           72            3                  EQU     −                10        NA        40     NA     NA
  WGY713 S2         8                   EQU           −                  80      40               320       40        40            
  DENV                                                                                                                              
  14                WGY065 S1           33            5                  QNS     −                320       160       160    320    160
  WGY065 S2         8                   \+            \+                 320     \>2,560          \>2,560   \>2,560   160           
  15                WGY071 S1           16            4                  QNS     −                20        10        40     160    20
  WGY071 S2         7                   \+            \+                 20      80               160       \>2,560   80            
  16                WGY321 S1           24            5                  −       −                160       160       40     80     20
  WGY321 S2         7                   \+            \+                 160     1280             160       160       80            
  17                WGY724 S1           28            4                  EQU     −                \<10      40        10     20     10
  WGY724 S2         7                   EQU           \+                 20      80               160       80        80            
  18                WGY727 S1           19            5                  −       \+               20        40        40     40     40
  WGY727 S2         6                   EQU           \+                 160     \>2,560          80        80        160           
  Flavivirus                                                                                                                        
  19                WGY089 S1           33            5                  QNS     \+               40        20        80     80     40
  WGY089 S2         8                   \+            \+                 80      20               80        160       40            
  20                WGY174 S1           3             4                  \+      \+               40        10        80     80     160
  WGY174 S2         5                   \+            \+                 320     10               320       80        320           
  21                WGY178 S1           20            3                  \+      −                80        40        80     \<10   \<10
  WGY178 S2         5                   \+            \+                 160     40               320       20        20            
  22                WGY516 S1           15            3                  QNS     \+               \<10      \<10      \<10   40     \<10
  WGY516 S2         5                   EQU           \+                 20      \<10             \<10      40        \<10          
  23                WGY575 S1           26            4                  EQU     −                20        20        40     20     10
  WGY575 S2         5                   \+            \+                 160     40               80        160       40            
  24                WGY674 S1           21            5                  −       −                40        \<10      \<10   \<10   \<10
  WGY674 S2         7                   \+            \+                 40      10               20        \<10      20            
  25                WGY684 S1           16            5                  \+      \+               80        \<10      10     40     10
  WGY684 S2         6                   \+            \+                 80      10               20        40        20            
  26                WGY708 S1           31            3                  \+      −                NA        NA        NA     NA     NA
  WGY708 S2         6                   \+            \+                 40      40               40        20        40            

^a^Ratios of samples optical densities divided by negative control were calculated; \<2, negative (−); 2--3 equivocal (EQU); \>3 positive (+).

^b^Calculated ELISA binding index results ≥40 U were considered positive (+), while \<40 U were considered negative (−).

S1, admission serum sample; S2, discharge serum sample; QNS, quantity not sufficient.

Two patients (WGY599 and 623) with confirmed JEV infection diagnosis had no detectable or low neutralizing antibodies to JEV or any DENV in their S1 specimen, suggesting that JEV was the first flavivirus that they encountered (primary flavivirus/JEV). These two patients had IgM-positive results to both JEV and DENV, however a ≥4-fold rise of anti-JEV PRNT~90~ titer and a ≥4-fold difference between anti-JEV PRNT~90~ titer and anti-DENVs titers were observed in their S2 specimen, indicating a low level of cross-reactivity in the cases of primary JEV/flavivirus infection.

Most of the patients with probable JEV diagnosis had neutralizing antibody response to DENV in their S1 sample, suggesting previous exposure to DENV. Although most of these probable JEV-infected patients had a higher neutralizing antibody titer to DENV compared to JEV in their S2 specimen, we believe that these patients were infected with JEV since all had no detectable DENV IgM in both S1 and S2 specimens with positive or equivocal JEV IgM in the S2 specimen. The phenomenon of higher serologic reactivity to the previous flavivirus infection than to the current infection is known as "original antigenic sin" and has been documented in a number of studies in human and animal models \[[@pntd.0008454.ref029]--[@pntd.0008454.ref033]\]. The mechanism of this phenomenon is not completely understood but is likely attributed to a preferential expansion of memory B cell clones generated from previous flavivirus infection that cross-react and recognize the current infecting heterologous flavivirus \[[@pntd.0008454.ref034]\]. In addition, the absence of DENV RNA detectable in S1 specimens by highly sensitive RT-PCR provides further evidence of JE diagnosis as opposed to dengue.

Four out of five (80%) patients diagnosed as DENV infection had high PRNT titer (≥1,280) to one or more DENV serotypes with detectable anti-DENV IgM in the S2 specimen. Similar to probable JEV-infected patients, neutralizing antibody against DENV was detectable in their S1 which suggest secondary DENV infection. This was also observed in patients with flavivirus infection diagnosis. However, in the flavivirus group, serological data is not sufficient to distinguish the likely infecting flavivirus.

The clinical characteristics of JEV-infected patients are provided in [Table 3](#pntd.0008454.t003){ref-type="table"} along with 177 confirmed DENV-infected patients identified by DENV NS1 antigen detection and/or RT-PCR from the same study cohort ([Fig 1](#pntd.0008454.g001){ref-type="fig"}). The age of the JE patients ranged from 4 to 72 years old (median 23 years old) and eight of 13 patients were male (62%) ([Table 3](#pntd.0008454.t003){ref-type="table"}). The most notable symptoms were malaise, nausea, and loss of appetite, which was observed in 85%, 69%, and 54% of the patients, respectively. Hematological investigations showed thrombocytopenia and leukopenia in nine (69%) and seven (54%) patients, respectively. Mean nadir thrombocyte count was 107 ± 74.2 × 10^3^/μl (median 94 × 10^3^/μl) while mean nadir leukocyte count was 4 ± 1 × 10^3^/μl (median 4 × 10^3^/μl) among all 13 patients. No neurological manifestations or rashes were reported. Notably, there were no statistically significant differences found in clinical characteristics between confirmed and probable JE cases except for lowest hemoglobin level (14.5 ± 1.3 vs 12.6 ± 1.3 g/dl, *P* = 0.0319).

10.1371/journal.pntd.0008454.t003

###### Characteristics of patients with JEV and DENV infection identified in this study.

![](pntd.0008454.t003){#pntd.0008454.t003g}

  Patient characteristics                      JEV (n = 13)[^a^](#t003fn002){ref-type="table-fn"}   DENV (n = 177)[^b^](#t003fn003){ref-type="table-fn"}   
  -------------------------------------------- ---------------------------------------------------- ------------------------------------------------------ ---------------
  Demographic                                                                                                                                              
                                               Sex, male                                            8 (62%)                                                84 (48%)
                                               Age                                                  23 (4−72)                                              24 (1−75)
  Duration of illness before admission, days   4 (2−7)                                              4 (2−7)                                                
  Hematology                                                                                                                                               
                                               Lowest hemoglobin, g/dl                              13 (10−16)                                             13 (9−17)
                                               Lowest leukocyte counts, 10^3^/μl                    4 (2−5)[^c^](#t003fn004){ref-type="table-fn"}          3 (1−8)
                                               Leukopenia (\<4,000/μl)                              7 (54%)[^d^](#t003fn005){ref-type="table-fn"}          144 (82%)
                                               Lowest thrombocyte counts, 10^3^/μl                  94 (24−258)                                            53 (0.03−508)
                                               Thrombocytopenia (\<150,000/μl)                      9 (69%)[^e^](#t003fn006){ref-type="table-fn"}          163 (92%)
                                               Highest hematocrit, %                                47 (33−89)[^f^](#t003fn007){ref-type="table-fn"}       43 (6−164)
  Clinical symptoms                                                                                                                                        
                                               Malaise                                              11 (85%)                                               153 (86%)
                                               Nausea                                               9 (69%)                                                143 (81%)
                                               Loss of appetite                                     7 (54%)                                                125 (71%)
                                               Myalgia                                              5 (39%)                                                87 (49%)
                                               Headache                                             4 (31%)[^g^](#t003fn008){ref-type="table-fn"}          105 (59%)
                                               Hemorrhage                                           3 (23%)                                                28 (16%)
                                               Arthralgia                                           2 (15%)                                                71 (40%)
                                               Vomiting                                             2 (15%)                                                72 (41%)
                                               Cough                                                1 (8%)                                                 15 (9%)
                                               Retro-orbital pain                                   1 (8%)                                                 38 (22%)
                                               Rash                                                 0 (0%)                                                 11 (6%)
                                               Diarrhea                                             0 (0%)                                                 4 (2%)
                                               Runny nose                                           0 (0%)                                                 4 (2%)
                                               Neck stiffness                                       0 (0%)                                                 1 (1%)
                                               Seizure                                              0 (0%)                                                 0 (0%)
                                               Abdominal pain                                       0 (0%)                                                 25 (14%)
                                               Altered mental status                                0 (0%)                                                 0 (0%)
                                               Paralysis                                            0 (0%)                                                 0 (0%)
                                               Glasgow Coma Scale \<15                              0 (0%)                                                 0 (0%)

Data are presented as number of patients (%) or median (range).

^a^Includes confirmed JEV (n = 5) and probable JEV (n = 8) infection.

^b^Includes confirmed DENV-infected patients identified by detection of DENV NS1 antigen detection and/or RT-PCR as depicted in [Fig 1](#pntd.0008454.g001){ref-type="fig"}.

^c^Statistically significant compared with DENV (*P* = 0.002).

^d^Statistically significant compared with DENV (*P* = 0.018).

^e^Statistically significant compared with DENV (*P* = 0.007).

^f^Statistically significant compared with DENV (*P* = 0.003).

^g^Statistically significant compared with DENV (*P* = 0.045).

Interestingly when compared with the dengue patients, JE patients were less likely to have leukopenia (54% vs 82%, *P* = 0.018), thrombocytopenia (69% vs 92%, *P* = 0.007), or headache (31% vs 59%, *P* = 0.045). JE patients were also found to have a higher hematocrit than dengue patients (median 47% vs 43%, *P* = 0.030) ([Table 3](#pntd.0008454.t003){ref-type="table"}). Furthermore, although our study plans did not include follow up assessment to determine long term outcome of the patients after discharge, all JE patients had resolved symptoms upon hospital discharge.

It is not clear from our data if there was any temporal distribution pattern of the JEV infection since our study was not conducted throughout the whole year and the limited number of identified JE cases prevented making such an analysis. However, out of the 13 JE cases, six cases occurred in May, two cases in July, and each one case in March, April, June, September, and October.

Discussion {#sec011}
==========

JEV was not previously considered a significant public health problem in Indonesia until nationwide studies in the early 2000s (based on syndromic surveillance and serologic assays) suggested nationwide JEV endemicity \[[@pntd.0008454.ref009]--[@pntd.0008454.ref011]\]. Although there are a number of laboratory tests to diagnose JEV infection, virus detection assays are not useful for diagnostic purposes due to low-level, transient viremia, making anti-JEV IgM ELISA the WHO recommended method for JEV diagnosis and surveillance \[[@pntd.0008454.ref035]\]. However, cross-reactive IgM antibodies have been detected in about 10% of DENV and JEV cases \[[@pntd.0008454.ref036],[@pntd.0008454.ref037]\]. Therefore, a conservative case definition was used here to define JEV infection based on IgM ELISA followed by confirmation with PRNT in both admission and discharge serum samples. This study confirmed JEV as a cause of non-encephalitic acute febrile illness in Bali, where both JEV and DENV co-circulate.

In this study population, confirmed and probable JEV infection were identified in 9% (13 out of 144) cases. From the thirteen JE patients diagnosed in this study, eleven were adults while only two were children. Previous studies showed that more than 80% of Indonesian children have experienced DENV infection at least once before the age of ten \[[@pntd.0008454.ref038]\], which likely explains the low prevalence of cases with no detectable or low neutralizing antibodies to JEV or any DENV in their S1 specimen (i.e. primary JEV/flavivirus infection) in our study. Further, the presence of pre-existing DENV antibodies in JEV-infected patients has recently been associated with better patient outcomes \[[@pntd.0008454.ref039]\]. Hence, the absence of severe or encephalitic disease in these subjects could be partly attributed to pre-existing DENV immunity.

Thrombocytopenia, prevalent in DENV-infected patients identified in this study, was also observed in 69% of the febrile JE cases, similar to the non-encephalitic JEV infections from Thailand \[[@pntd.0008454.ref022]\]. Malaise, nausea, loss of appetite, myalgia, and headache were the major symptoms reported in the JEV cases here, similar to those reported previously \[[@pntd.0008454.ref022]\]. However, these symptoms were also present in DENV-infected patients at similar frequency except for headache which was less observed in JE cases. While this study suggests that thrombocytopenia, leukopenia, and lower hematocrit were less likely to be found in non-encephalitic JE compared with dengue cases, further studies are needed to confirm these findings.

JEV is routinely included in the diagnostic algorithm of AES in endemic areas of Indonesia. However, reports of JEV as the cause of non-encephalitic illness by using a virus specific PRNT confirmatory assay are lacking in Indonesia. The use of PRNT in this study was vital in confirming JEV infection especially in cases where anti-JEV and -DENV IgM were both detected as exemplified in patients WGY599, 623, 726, and 733. Unfortunately, there is limited laboratory capacity in Indonesia to perform PRNT or detect flaviviruses other than DENV. The role of other vector-borne viruses, including JEV, as causes of febrile illness or encephalitis has therefore likely been underestimated. As such, JEV remains an important public health concern in Indonesia and the transmission of JEV warrants further investigation.

This study is limited by the number of non-encephalitic JE cases identified which does not allow for a sound stratified analysis of the results particularly regarding the clinical features. Furthermore, the higher prevalence of adults over children identified in the study might be due to lack of appropriate population denominator data. The incidence of non-encephalitic JE might potentially be higher in children if the data from this study were adjusted by age stratified population denominator (i.e. the number of susceptible children during the study period).

In summary, this work demonstrates JEV infection in non-encephalitic acute febrile illness patients identified using robust serological assays. Although JEV vaccination has recently been introduced in Bali \[[@pntd.0008454.ref040]\] with reported coverage of 94% in 2018 \[[@pntd.0008454.ref041]\], it has not been widely implemented throughout Indonesia. Hence, further JEV surveillance is required to fully reveal the epidemiology of JE disease in humans. This report on JEV as the cause of acute febrile illness in Bali is fundamental to characterizing JE epidemiology, identifying high-risk areas, and documenting the impact of prevention measures in Indonesia.
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20 Apr 2020

Dear Myint,

Thank you very much for submitting your manuscript \"Japanese Encephalitis Virus Infection in Non-Encephalitic Acute Febrile Illness Patients\" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers\' comments.

AE comments:

1\) Please be sure to respond to the reviewer comments sent as separate files.

2\) Please provide a brief description of the collection of clinical and clinical laboratory data (Table 2), e.g., when and how frequently this was collected.

3\) Please comment on whether the clinical characteristics were similar in the cases defined as confirmed and probably JE (Table 2).

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers\' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

\[1\] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

\[2\] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don\'t hesitate to contact us if you have any questions or comments.

Sincerely,

Alan L Rothman, MD

Associate Editor

PLOS Neglected Tropical Diseases

Scott Weaver

Deputy Editor

PLOS Neglected Tropical Diseases

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

AE comments:

1\) Please be sure to respond to the reviewer comments sent as separate files.

2\) Please provide a brief description of the collection of clinical and clinical laboratory data (Table 2), e.g., when and how frequently this was collected.

3\) Please comment on whether the clinical characteristics were similar in the cases defined as confirmed and probably JE (Table 2).

Reviewer\'s Responses to Questions

**Key Review Criteria Required for Acceptance?**

As you describe the new analyses required for acceptance, please consider the following:

**Methods**

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer \#1: The study had clearly stated objectives and design for an observation in a hospital population. I believe the study reports on a sufficient number of cases to support the findings but the nature of the study does not requirer statistical analyses. My only comment on design is an editorial one. Use of RT-PCR for dengue analysis of S1 is described under \"Study site, patient recruitment and sample collection\". This is fine, but use of PCR should appear under Methods in the same way that Elisa, PRNT etc. do. Either the description of Rt-PCR should be moved there under a heading of Rt-PCR or there should be a note in the methods under an RT-PCR heading that refers to the description in the Study site section. I think the former is preferable. I have no concerns about ethical conduct of the study.

Reviewer \#2: The objective of the study was articulated well and the study design was appropriate for addressing the objective.

Reviewer \#3: (No Response)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: I believe that the results are presented clearly and match the analysis plan. The category criteria for confirmed and probable JE or dengue are, of necessity, complex and the textual explanation of why some probable JE cases are not dengue is critical and helps one understand the small +/- data presented in the Table. I would suggest, however that the RT-PCR data for dengue be cited in the results as further evidence in support of those probable cases fitting JE more closely, because RT-PCR is highly sensitive and specific in the febrile period for dengue diagnosis. It is reported in a sentence in the manuscript that there were no positive RT-PCR for dengue or JE. That is unsurprising for JE as it is quite rare to have high enough sustained viremia to detect JE infection with PCR, but not so with dengue. The fact that PCR was negative for dengue in the Probably JE cases adds to the argument made on the basis of serologic criteria that the JE probable cases were in fact more likely to be JE. I think it helps your case if you state that clearly in this section of the results.

Reviewer \#2: The results of the study were presented clearly, however, there was room for inclusion of more information.

Reviewer \#3: (No Response)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#1: The conclusions are supported by the data and I believe, as noted above, reporting of RT-PCR negative dengue tests in the results would make an even stronger case. There is no real discussion of limitations other than the difficulty of flavivirus serologic cross-reactivity. The small numbers don\'t allow for any stratification of results and statistical analysis and that should be described as a limitation. I think the finding of a clinical, non-encephalitic state for JE, along with that described in reference 22, is very important. Most people think JE presents only as severe illness or asymptomatic infection. It is helpful to understand that there is, not surprisingly, an intermediate circumstance. My last comment is that the authors should consider that the odd adult distribution is likely due to the fact that this is numerator only study. Seeming predominance of adult cases of JE is common where only numerator data is available. The 15-20% of individuals who are not infected as children and acquire the virus later in life can be quite numerous in a population. In most circumstances where vaccine has not been broadly applied, adjusting the numerator data by age stratified population denominators shows that the incidence is much higher in children under 15 years of age. The authors should address the lack of population denominator data as another key limitation of the study.

Reviewer \#2: The conclusion of the study was supported by the data presented.

Reviewer \#3: (No Response)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Editorial and Data Presentation Modifications?**

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#1: I felt that the editorial suggestions that I have are better addressed in the context of the questions posed for review in the above sections and have taken that approach. I have no more suggestions here.

Reviewer \#2: (No Response)

Reviewer \#3: (No Response)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: I think this is of high significance and am grateful to see that the study has been undertaken. I have seen such information from fever surveillance in one country where clinical symptoms were not readily available. This study makes it clear that these cases are very likely JE and that they have little symptomatology other, than the 30% of cases with headache, that would make any one think of JE encephalitis. It is very helpful to broaden the understanding of the spectrum of JE disease.

Reviewer \#2: This would be a missed opportunity if some additional results were not included as mentioned in the review comments.

Reviewer \#3: The draft manuscript describes a retrospective analyses of paired-serum samples collected from febrile, not encephalitic, patients in Bali, Indonesia. A significant proportion of these samples demonstrate seroconversion to JEV, perhaps underscoring the need of more robust surveillance in the region and the need for JEV vaccinations. Nonetheless, as is, the draft lacks more thorough and consistent testing to properly provide for evidence of JEV seroconversions. Before acceptance, authors should be given an opportunity to address findings in attached letter.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosntds/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, [https://pacev2.apexcovantage.com. PACE](https://pacev2.apexcovantage.com. PACE) helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Data Requirements:

Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <https://journals.plos.org/plosntds/s/submission-guidelines#loc-methods>
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5 Jun 2020

Dear Myint,

We are pleased to inform you that your manuscript \'Japanese Encephalitis Virus Infection in Non-Encephalitic Acute Febrile Illness Patients\' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Alan L Rothman, MD

Associate Editor

PLOS Neglected Tropical Diseases

Scott Weaver

Deputy Editor

PLOS Neglected Tropical Diseases

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
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24 Jun 2020

Dear Myint,

We are delighted to inform you that your manuscript, \"Japanese Encephalitis Virus Infection in Non-Encephalitic Acute Febrile Illness Patients,\" has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

[^1]: The authors have declared that no competing interests exist.
